Monographie - Esomeprazole sodium

Senaste uppdateringen :
08/05/2024

Esomeprazole sodium

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Adptor	Mexiko
Axagon	Italien
Axiago	Sverige
Cativa	Sverige
Cronopep	Colombia, Peru
Eliprot	Ecuador
Emune	Ecuador
Epral	Chile
Esio	Ecuador
Esmonat	Indien, Turkiet
Esoblok	Turkiet
Esofax	Ecuador
Esolium	Peru
Esomep	Schweiz
Esomeprazol	Chile, Colombia, Ecuador, Rumänien, Spanien
Esomeprazole	Förenta Staterna
Esopral	Italien, Sverige
Esopran	Peru
Esoton Plus	Peru
Esoz	Colombia, Indien
Ezole	Peru
Gletop	Venezuela
Inexium	Frankrike
Milenium	Ecuador
Nexiam	Belgien, Luxemburg
Nexium	Argentina, Chile, Colombia, Ecuador, Egypten, Förenade Arabemiraten, Förenta Staterna, Grekland, Irland, Island, Italien, Malaysia, Mexiko, Norge, Portugal, Rumänien, Saudi-Arabien, Schweiz, Spanien, Storbritannien, Sverige, Turkiet, Tyskland, Venezuela
Redica	Sverige
Refexxin	Sverige

Hänvisningar : Esomeprazole sodium

	Typ	Publikation
1506	Tidningen	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Tidningen	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2262	Tidningen	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Tidningen	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270	Tidningen	Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284	Laboratorium	Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics Astra Zenaca 2007
2311	Tidningen	Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. J Clin Pharm Ther 2009 ; 34: 25-31.
3249	Tidningen	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Tidningen	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Tidningen	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429	Tidningen	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3827	Affisch	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Affisch	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Affisch	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Tidningen	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Tidningen	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Tidningen	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Tidningen	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Tidningen	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4465	Tidningen	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528	Tidningen	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	Tidningen	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales